[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100285990":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":95,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HCV Genotype 1 Participants",null,"Participants receiving paritaprevir\u002Fritonavir\u002Fombitasvir with dasabuvir (Viekirax®\u002FExviera®, 3D regimen)",[13],{"name":14,"affiliation":5,"role":15},"AbbVie Inc.","STUDY_DIRECTOR",[17,30,39,48,57],{"facility":18,"status":10,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Kantonsspital St. Gallen","Sankt Gallen","Canton of St. Gallen","9007","Switzerland","CH",{"type":25,"coordinates":26},"Point",[27,28],9.37477,47.42391,{"lat":28,"lon":27},{"facility":31,"status":10,"city":32,"state":10,"zip":33,"country":22,"countryCode":23,"cosmosGeoPoint":34,"geoPoint":38,"contacts":10},"Inselspital, Universitaetsklin","Bern","3010",{"type":25,"coordinates":35},[36,37],7.44744,46.94809,{"lat":37,"lon":36},{"facility":40,"status":10,"city":41,"state":10,"zip":42,"country":22,"countryCode":23,"cosmosGeoPoint":43,"geoPoint":47,"contacts":10},"Fondazione Epatocentro Ticino","Lugano","6900",{"type":25,"coordinates":44},[45,46],8.96004,46.01008,{"lat":46,"lon":45},{"facility":49,"status":10,"city":50,"state":10,"zip":51,"country":22,"countryCode":23,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Hopital Neuchatelois","Neuchâtel","CH-2000",{"type":25,"coordinates":53},[54,55],6.931,46.99179,{"lat":55,"lon":54},{"facility":58,"status":10,"city":59,"state":10,"zip":60,"country":22,"countryCode":23,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Universitaetsspital Zuerich","Zurich","8091",{"type":25,"coordinates":62},[63,64],8.55,47.36667,{"lat":64,"lon":63},{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100285990","quality-of-life-measurement-in-treatment-nave-patients-with-hepatitis-c-virus-hcv-genotype-1-gt1-suffering-from-fatigue-and-receiving-ombitasvir-paritaprevir-and-ritonavir-and-dasabuvir-viekiraxexviera-100285990",true,"NCT03002818","Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®\u002FExviera®)","Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®\u002FExviera®; 3D Regimen): The HEMATITE Study","HEMATITE","Inclusion Criteria:\n\n* Treatment-naïve participants\n* Mono-infected participants with chronic HCV GT1\n* Non-cirrhotic participants\n* Participants with debilitating fatigue (Fatigue Severity Scale \\[FSS\\] greater than or equal to 4)\n\nExclusion Criteria:\n\n* Participants with sources of fatigue other than HCV (especially, severe depression, cancer and hormonal disorders causing clinically significant fatigue)\n* Participants with conditions that do not allow to adhere to protocol and use of the device at investigator's discretion\n* Participants who are wheelchair dependent",false,"ALL","18 Years","99 Years",{"count":81,"type":82},41,"ACTUAL","OBSERVATIONAL","This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir\u002Fritonavir\u002Fombitasvir with dasabuvir regimen (Viekirax®\u002FExviera®, 3D regimen) on total daytime physical activity and fatigue in participants with HCV GT1.",[86],"Chronic Hepatitis C Virus (HCV)",[88,89,90,91,92,93,94],"Chronic Hepatitis C (HCV)","Genotype 1","Paritaprevir","Ritonavir","ombitasvir","Dasabuvir","Sustained Virological Response","COMPLETED","2019-09-30",{"date":98,"type":82},"2019-10-23",{"date":100,"type":82},"2017-03-01",{"date":102,"type":82},"2018-04-25",{"name":5,"class":6},5]